Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 995

1.

An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.

Tsukamoto H, Kubota K, Shichiku A, Maekawa M, Mano N, Yagita H, Ohta S, Tomioka Y.

Immunology. 2019 Oct;158(2):136-149. doi: 10.1111/imm.13095.

PMID:
31515801
2.

Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice.

Bialojan A, Sohl J, Rausch J, Aranda Lopez P, Denny M, Langguth P, Hartmann AK, Yagita H, Probst HC, Schild H, Radsak MP.

Eur J Immunol. 2019 Aug 8. doi: 10.1002/eji.201848039. [Epub ahead of print]

PMID:
31393597
3.

Blockade of PD-1 Attenuated Post-Sepsis Aspergillosis via The Activation Of IFN-γ and The Dampening of IL-10.

Vu CTB, Thammahong A, Yagita H, Azuma M, Hirankarn N, Ritprajak P, Leelahavanichkul A.

Shock. 2019 Jul 11. doi: 10.1097/SHK.0000000000001392. [Epub ahead of print]

PMID:
31306346
4.

JunB plays a crucial role in development of regulatory T cells by promoting IL-2 signaling.

Katagiri T, Yamazaki S, Fukui Y, Aoki K, Yagita H, Nishina T, Mikami T, Katagiri S, Shiraishi A, Kimura S, Tateda K, Sumimoto H, Endo S, Kameda H, Nakano H.

Mucosal Immunol. 2019 Sep;12(5):1104-1117. doi: 10.1038/s41385-019-0182-0. Epub 2019 Jul 8.

PMID:
31285535
5.

Lymph Node Mesenchymal and Endothelial Stromal Cells Cooperate via the RANK-RANKL Cytokine Axis to Shape the Sinusoidal Macrophage Niche.

Camara A, Cordeiro OG, Alloush F, Sponsel J, Chypre M, Onder L, Asano K, Tanaka M, Yagita H, Ludewig B, Flacher V, Mueller CG.

Immunity. 2019 Jun 18;50(6):1467-1481.e6. doi: 10.1016/j.immuni.2019.05.008. Epub 2019 Jun 11.

PMID:
31201093
6.

An anti-RANKL treatment reduces muscle inflammation and dysfunction and strengthens bone in dystrophic mice.

Hamoudi D, Marcadet L, Piette Boulanger A, Yagita H, Bouredji Z, Argaw A, Frenette J.

Hum Mol Genet. 2019 Sep 15;28(18):3101-3112. doi: 10.1093/hmg/ddz124.

PMID:
31179501
7.

BTLA stimulation protects against atherosclerosis by regulating follicular B cells.

Douna H, Amersfoort J, Schaftenaar FH, Kröner MJ, Kiss MB, Slütter B, Depuydt MAC, Kleijn MNAB, Wezel A, Smeets H, Yagita H, Binder CJ, Bot I, van Puijvelde GHM, Kuiper J, Foks AC.

Cardiovasc Res. 2019 May 31. pii: cvz129. doi: 10.1093/cvr/cvz129. [Epub ahead of print]

PMID:
31150053
8.

Endothelial Cells in the Decidual Bed Are Potential Therapeutic Targets for Preterm Birth Prevention.

Deng W, Yuan J, Cha J, Sun X, Bartos A, Yagita H, Hirota Y, Dey SK.

Cell Rep. 2019 May 7;27(6):1755-1768.e4. doi: 10.1016/j.celrep.2019.04.049.

9.

Addendum: A FRET biosensor for necroptosis uncovers two different modes of the release of DAMPs.

Murai S, Yamaguchi Y, Shirasaki Y, Yamagishi M, Shindo R, Hildebrand JM, Miura R, Nakabayashi O, Totsuka M, Tomida T, Adachi-Akahane S, Uemura S, Silke J, Yagita H, Miura M, Nakano H.

Nat Commun. 2019 Apr 25;10(1):1923. doi: 10.1038/s41467-019-09536-9.

10.

CD155-Transducing Signaling through TIGIT Plays an Important Role in Transmission of Tolerant State and Suppression Capacity.

Negishi N, Sato T, Yamashita-Kanemaru Y, Shibuya K, Uchida K, Kametani Y, Yagita H, Kitaura J, Okumura K, Habu S.

Immunohorizons. 2018 Nov 16;2(10):338-348. doi: 10.4049/immunohorizons.1800033.

PMID:
31022697
11.

Depletion of PD-1-positive cells ameliorates autoimmune disease.

Zhao P, Wang P, Dong S, Zhou Z, Cao Y, Yagita H, He X, Zheng SG, Fisher SJ, Fujinami RS, Chen M.

Nat Biomed Eng. 2019 Apr;3(4):292-305. doi: 10.1038/s41551-019-0360-0. Epub 2019 Mar 4.

12.

Notch Signaling in Nestin-Expressing Cells in the Bone Marrow Maintains Erythropoiesis via Macrophage Integrity.

Sakamoto T, Obara N, Nishikii H, Kato T, Cao-Sy L, Fujimura R, Yagita H, Sakata-Yanagimoto M, Takahashi S, Chiba S.

Stem Cells. 2019 Jul;37(7):924-936. doi: 10.1002/stem.3011. Epub 2019 Apr 15.

PMID:
30932281
13.

Integrin β1 Promotes the Interaction of Murine IgG3 with Effector Cells.

Hawk CS, Coelho C, Oliveira DSL, Paredes V, Albuquerque P, Bocca AL, Correa Dos Santos A, Rusakova V, Holemon H, Silva-Pereira I, Felipe MSS, Yagita H, Nicola AM, Casadevall A.

J Immunol. 2019 May 1;202(9):2782-2794. doi: 10.4049/jimmunol.1701795. Epub 2019 Mar 20.

PMID:
30894426
14.

Nr5a1 suppression during the murine fetal period optimizes ovarian development by fine-tuning Notch signaling.

Nomura R, Kashimada K, Suzuki H, Zhao L, Tsuji-Hosokawa A, Yagita H, Takagi M, Kanai Y, Bowles J, Koopman P, Kanai-Azuma M, Morio T.

J Cell Sci. 2019 Apr 15;132(8). pii: jcs223768. doi: 10.1242/jcs.223768.

15.

Beneficial effects of sunitinib on tumor microenvironment and immunotherapy targeting death receptor5.

Tsukita Y, Okazaki T, Ebihara S, Komatsu R, Nihei M, Kobayashi M, Hirano T, Sugiura H, Tamada T, Tanaka N, Sato Y, Yagita H, Ichinose M.

Oncoimmunology. 2018 Nov 13;8(2):e1543526. doi: 10.1080/2162402X.2018.1543526. eCollection 2019.

PMID:
30713805
16.

Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells.

Gemta LF, Siska PJ, Nelson ME, Gao X, Liu X, Locasale JW, Yagita H, Slingluff CL Jr, Hoehn KL, Rathmell JC, Bullock TNJ.

Sci Immunol. 2019 Jan 25;4(31). pii: eaap9520. doi: 10.1126/sciimmunol.aap9520.

PMID:
30683669
17.

Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance.

Muraoka D, Seo N, Hayashi T, Tahara Y, Fujii K, Tawara I, Miyahara Y, Okamori K, Yagita H, Imoto S, Yamaguchi R, Komura M, Miyano S, Goto M, Sawada SI, Asai A, Ikeda H, Akiyoshi K, Harada N, Shiku H.

J Clin Invest. 2019 Mar 1;129(3):1278-1294. doi: 10.1172/JCI97642. Epub 2019 Feb 11.

18.

Maternal RANKL Reduces the Osteopetrotic Phenotype of Null Mutant Mouse Pups.

Navet B, Vargas-Franco JW, Gama A, Amiaud J, Choi Y, Yagita H, Mueller CG, Rédini F, Heymann D, Castaneda B, Lézot F.

J Clin Med. 2018 Nov 8;7(11). pii: E426. doi: 10.3390/jcm7110426.

19.

A FRET biosensor for necroptosis uncovers two different modes of the release of DAMPs.

Murai S, Yamaguchi Y, Shirasaki Y, Yamagishi M, Shindo R, Hildebrand JM, Miura R, Nakabayashi O, Totsuka M, Tomida T, Adachi-Akahane S, Uemura S, Silke J, Yagita H, Miura M, Nakano H.

Nat Commun. 2018 Oct 26;9(1):4457. doi: 10.1038/s41467-018-06985-6.

20.

The Intrinsic and Extrinsic Implications of RANKL/RANK Signaling in Osteosarcoma: From Tumor Initiation to Lung Metastases.

Navet B, Ando K, Vargas-Franco JW, Brion R, Amiaud J, Mori K, Yagita H, Mueller CG, Verrecchia F, Dumars C, Heymann MF, Heymann D, Lézot F.

Cancers (Basel). 2018 Oct 24;10(11). pii: E398. doi: 10.3390/cancers10110398.

21.

CD8+ T-cells contribute to lesion stabilization in advanced atherosclerosis by limiting macrophage content and CD4+ T-cell responses.

van Duijn J, Kritikou E, Benne N, van der Heijden T, van Puijvelde GH, Kröner MJ, Schaftenaar FH, Foks AC, Wezel A, Smeets H, Yagita H, Bot I, Jiskoot W, Kuiper J, Slütter B.

Cardiovasc Res. 2019 Mar 15;115(4):729-738. doi: 10.1093/cvr/cvy261.

PMID:
30335148
22.

Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients.

Tallón de Lara P, Cecconi V, Hiltbrunner S, Yagita H, Friess M, Bode B, Opitz I, Vrugt B, Weder W, Stolzmann P, Felley-Bosco E, Stahel RA, Tischler V, Britschgi C, Soldini D, van den Broek M, Curioni-Fontecedro A.

Clin Cancer Res. 2018 Dec 15;24(24):6345-6354. doi: 10.1158/1078-0432.CCR-18-1231. Epub 2018 Aug 28.

PMID:
30154226
23.

Removal of Pre-Existing Periodontal Inflammatory Condition before Tooth Extraction Ameliorates Medication-Related Osteonecrosis of the Jaw-Like Lesion in Mice.

Kim T, Kim S, Song M, Lee C, Yagita H, Williams DW, Sung EC, Hong C, Shin KH, Kang MK, Park NH, Kim RH.

Am J Pathol. 2018 Oct;188(10):2318-2327. doi: 10.1016/j.ajpath.2018.06.019. Epub 2018 Jul 27.

24.

Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy.

Dufresne SS, Boulanger-Piette A, Bossé S, Argaw A, Hamoudi D, Marcadet L, Gamu D, Fajardo VA, Yagita H, Penninger JM, Russell Tupling A, Frenette J.

Acta Neuropathol Commun. 2018 Apr 24;6(1):31. doi: 10.1186/s40478-018-0533-1.

25.

Antigen-specific Helios- , Neuropilin-1- Tregs induce apoptosis of autoreactive B cells via PD-L1.

Gotot J, Dhana E, Yagita H, Kaiser R, Ludwig-Portugall I, Kurts C.

Immunol Cell Biol. 2018 Sep;96(8):852-862. doi: 10.1111/imcb.12053. Epub 2018 May 2.

PMID:
29617057
26.

Blockade of TNF receptor superfamily 1 (TNFR1)-dependent and TNFR1-independent cell death is crucial for normal epidermal differentiation.

Piao X, Miura R, Miyake S, Komazawa-Sakon S, Koike M, Shindo R, Takeda J, Hasegawa A, Abe R, Nishiyama C, Mikami T, Yagita H, Uchiyama Y, Nakano H.

J Allergy Clin Immunol. 2019 Jan;143(1):213-228.e10. doi: 10.1016/j.jaci.2018.02.043. Epub 2018 Mar 27.

PMID:
29596938
27.

Anti-CD11b antibody treatment suppresses the osteoclast generation, inflammatory cell infiltration, and autoantibody production in arthritis-prone FcγRIIB-deficient mice.

Ohtsuji M, Lin Q, Okazaki H, Takahashi K, Amano H, Yagita H, Nishimura H, Hirose S.

Arthritis Res Ther. 2018 Feb 8;20(1):25. doi: 10.1186/s13075-018-1523-1.

28.

Perforin proteostasis is regulated through its C2 domain: supra-physiological cell death mediated by T431D-perforin.

Brennan AJ, Law RHP, Conroy PJ, Noori T, Lukoyanova N, Saibil H, Yagita H, Ciccone A, Verschoor S, Whisstock JC, Trapani JA, Voskoboinik I.

Cell Death Differ. 2018 Aug;25(8):1517-1529. doi: 10.1038/s41418-018-0057-z. Epub 2018 Feb 7.

29.

The CD300e molecule in mice is an immune-activating receptor.

Isobe M, Izawa K, Sugiuchi M, Sakanishi T, Kaitani A, Takamori A, Maehara A, Matsukawa T, Takahashi M, Yamanishi Y, Oki T, Uchida S, Uchida K, Ando T, Maeda K, Nakano N, Yagita H, Takai T, Ogawa H, Okumura K, Kitamura T, Kitaura J.

J Biol Chem. 2018 Mar 9;293(10):3793-3805. doi: 10.1074/jbc.RA117.000696. Epub 2018 Jan 22.

30.

Editorial: Ying and Yang Members of the Tumor Necrosis Factor Superfamily: Friends or Foes in Immune-Mediated Diseases and Cancer.

Giwa A, Ahmed R, Donner T, Yagita H, Hamad ARA.

Front Immunol. 2017 Nov 23;8:1584. doi: 10.3389/fimmu.2017.01584. eCollection 2017. No abstract available.

31.

A variant of death-receptor 3 associated with rheumatoid arthritis interferes with apoptosis-induction of T cell.

Hashiramoto A, Konishi Y, Murayama K, Kawasaki H, Yoshida K, Tsumiyama K, Tanaka K, Mizuhara M, Shiotsuki T, Kitamura H, Komai K, Kimura T, Yagita H, Shiozawa K, Shiozawa S.

J Biol Chem. 2018 Feb 9;293(6):1933-1943. doi: 10.1074/jbc.M117.798884. Epub 2017 Nov 27.

32.

Autophagy-dependent regulation of tumor metastasis by myeloid cells.

Jinushi M, Morita T, Xu Z, Kinoshita I, Dosaka-Akita H, Yagita H, Kawakami Y.

PLoS One. 2017 Jul 7;12(7):e0179357. doi: 10.1371/journal.pone.0179357. eCollection 2017.

33.

Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity.

Nawaf MG, Ulvmar MH, Withers DR, McConnell FM, Gaspal FM, Webb GJ, Jones ND, Yagita H, Allison JP, Lane PJL.

J Immunol. 2017 Aug 1;199(3):974-981. doi: 10.4049/jimmunol.1700088. Epub 2017 Jun 23.

34.

Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors.

Fujii K, Miyahara Y, Harada N, Muraoka D, Komura M, Yamaguchi R, Yagita H, Nakamura J, Sugino S, Okumura S, Imoto S, Miyano S, Shiku H.

Oncoimmunology. 2017 Mar 20;6(5):e1306617. doi: 10.1080/2162402X.2017.1306617. eCollection 2017.

35.

Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.

Ahern E, Harjunpää H, Barkauskas D, Allen S, Takeda K, Yagita H, Wyld D, Dougall WC, Teng MWL, Smyth MJ.

Clin Cancer Res. 2017 Oct 1;23(19):5789-5801. doi: 10.1158/1078-0432.CCR-17-0606. Epub 2017 Jun 20.

36.

Expansion of FasL-Expressing CD5+ B Cells in Type 1 Diabetes Patients.

Saxena A, Yagita H, Donner TW, Hamad ARA.

Front Immunol. 2017 Apr 7;8:402. doi: 10.3389/fimmu.2017.00402. eCollection 2017.

37.

An Anti-Programmed Death-1 Antibody (αPD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional αPD-1 Nanoparticle.

Zhao P, Atanackovic D, Dong S, Yagita H, He X, Chen M.

Mol Pharm. 2017 May 1;14(5):1494-1500. doi: 10.1021/acs.molpharmaceut.6b01021. Epub 2017 Apr 19.

38.

Notch Ligand DLL4 Alleviates Allergic Airway Inflammation via Induction of a Homeostatic Regulatory Pathway.

Huang MT, Chen YL, Lien CI, Liu WL, Hsu LC, Yagita H, Chiang BL.

Sci Rep. 2017 Mar 6;7:43535. doi: 10.1038/srep43535.

39.

PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.

Asano T, Meguri Y, Yoshioka T, Kishi Y, Iwamoto M, Nakamura M, Sando Y, Yagita H, Koreth J, Kim HT, Alyea EP, Armand P, Cutler CS, Ho VT, Antin JH, Soiffer RJ, Maeda Y, Tanimoto M, Ritz J, Matsuoka KI.

Blood. 2017 Apr 13;129(15):2186-2197. doi: 10.1182/blood-2016-09-741629. Epub 2017 Feb 1.

40.

Radiation-Induced Enhancement of Antitumor T-cell Immunity by VEGF-Targeted 4-1BB Costimulation.

Schrand B, Verma B, Levay A, Patel S, Castro I, Benaduce AP, Brenneman R, Umland O, Yagita H, Gilboa E, Ishkanian A.

Cancer Res. 2017 Mar 15;77(6):1310-1321. doi: 10.1158/0008-5472.CAN-16-2105. Epub 2017 Jan 12.

41.

Protective Role of ICOS and ICOS Ligand in Corneal Transplantation and in Maintenance of Immune Privilege.

Kunishige T, Taniguchi H, Terada M, Akiba H, Yagita H, Abe R, Hori J.

Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6815-6823. doi: 10.1167/iovs.16-20644.

PMID:
28002569
42.

TRAIL signaling is proinflammatory and proviral in a murine model of rhinovirus 1B infection.

Girkin JL, Hatchwell LM, Collison AM, Starkey MR, Hansbro PM, Yagita H, Foster PS, Mattes J.

Am J Physiol Lung Cell Mol Physiol. 2017 Jan 1;312(1):L89-L99. doi: 10.1152/ajplung.00200.2016. Epub 2016 Nov 11.

43.

SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.

Xue W, Brentville VA, Symonds P, Cook KW, Yagita H, Metheringham RL, Durrant LG.

Oncotarget. 2016 Dec 13;7(50):83088-83100. doi: 10.18632/oncotarget.13070.

44.

Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor.

Ngiow SF, Young A, Blake SJ, Hill GR, Yagita H, Teng MW, Korman AJ, Smyth MJ.

Cancer Res. 2016 Nov 1;76(21):6266-6277. Epub 2016 Sep 9.

45.

Acute Virus Control Mediated by Licensed NK Cells Sets Primary CD8+ T Cell Dependence on CD27 Costimulation.

Teoh JJ, Gamache AE, Gillespie AL, Stadnisky MD, Yagita H, Bullock TN, Brown MG.

J Immunol. 2016 Dec 1;197(11):4360-4370. Epub 2016 Oct 24.

46.

Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells.

Beyranvand Nejad E, van der Sluis TC, van Duikeren S, Yagita H, Janssen GM, van Veelen PA, Melief CJ, van der Burg SH, Arens R.

Cancer Res. 2016 Oct 15;76(20):6017-6029. Epub 2016 Aug 28.

47.

Pharmacologic inhibition of Notch signaling suppresses food antigen-induced mucosal mast cell hyperplasia.

Honjo A, Nakano N, Yamazaki S, Hara M, Uchida K, Kitaura J, Nishiyama C, Yagita H, Ohtsuka Y, Ogawa H, Okumura K, Shimizu T.

J Allergy Clin Immunol. 2017 Mar;139(3):987-996.e10. doi: 10.1016/j.jaci.2016.05.046. Epub 2016 Jul 16.

PMID:
27555456
48.

SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade.

Xue W, Metheringham RL, Brentville VA, Gunn B, Symonds P, Yagita H, Ramage JM, Durrant LG.

Oncoimmunology. 2016 Apr 22;5(6):e1169353. doi: 10.1080/2162402X.2016.1169353. eCollection 2016 Jun.

49.

Microfold Cells Actively Translocate Mycobacterium tuberculosis to Initiate Infection.

Nair VR, Franco LH, Zacharia VM, Khan HS, Stamm CE, You W, Marciano DK, Yagita H, Levine B, Shiloh MU.

Cell Rep. 2016 Aug 2;16(5):1253-1258. doi: 10.1016/j.celrep.2016.06.080. Epub 2016 Jul 21.

50.

IL-17A-producing CD30(+) Vδ1 T cells drive inflammation-induced cancer progression.

Kimura Y, Nagai N, Tsunekawa N, Sato-Matsushita M, Yoshimoto T, Cua DJ, Iwakura Y, Yagita H, Okada F, Tahara H, Saiki I, Irimura T, Hayakawa Y.

Cancer Sci. 2016 Sep;107(9):1206-14. doi: 10.1111/cas.13005. Epub 2016 Sep 1.

Supplemental Content

Loading ...
Support Center